A carregar...
Prognostic biomarkers for immunotherapy with ipilimumab in metastatic melanoma
New therapies, including the anti‐cytotoxic T lymphocyte antigen (CTLA)‐4 antibody, ipilimumab, is approved for metastatic melanoma. Prognostic biomarkers need to be identified, because the treatment has serious side effects. Serum samples were obtained before and during treatment from 56 patients w...
Na minha lista:
| Publicado no: | Clin Exp Immunol |
|---|---|
| Main Authors: | , , , , , , , , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
John Wiley and Sons Inc.
2019
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6591141/ https://ncbi.nlm.nih.gov/pubmed/30821848 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/cei.13283 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|